Mapping naso-ocular symptom scores to EQ-5D-5L utility values in Japanese cedar pollinosis
Background: The total naso-ocular symptom score (TSS) is widely used as an endpoint to evaluate the severity of seasonal allergic rhinitis. However, it is not a generic preference-based measure. We sought to develop an algorithm for mapping between the TSS and health utility in Japanese cedar pollin...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-04-01
|
| Series: | Allergology International |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1323893021001416 |
| _version_ | 1811329495515267072 |
|---|---|
| author | Hiroshi Kumanomidou Kengo Kanai Aiko Oka Takenori Haruna Yuji Hirata Sei-ichiro Makihara Takaya Higaki Maki Akamatsu Yoshitaka Okamoto Shunya Ikeda Mitsuhiro Okano |
| author_facet | Hiroshi Kumanomidou Kengo Kanai Aiko Oka Takenori Haruna Yuji Hirata Sei-ichiro Makihara Takaya Higaki Maki Akamatsu Yoshitaka Okamoto Shunya Ikeda Mitsuhiro Okano |
| author_sort | Hiroshi Kumanomidou |
| collection | DOAJ |
| description | Background: The total naso-ocular symptom score (TSS) is widely used as an endpoint to evaluate the severity of seasonal allergic rhinitis. However, it is not a generic preference-based measure. We sought to develop an algorithm for mapping between the TSS and health utility in Japanese cedar pollinosis (JCP). We also performed a cost-utility analysis of sublingual immunotherapy (SLIT) for JCP by using this algorithm. Methods: Patients with JCP filled out the TSS questionnaire and EQ-5D-5L simultaneously during the pollen season in 2019 and in 2020. We estimated a direct utility mapping model by regressing responses to individual TSS questions directly onto utility. The incremental cost-effectiveness ratio (ICER) of active SLIT to a placebo was determined by examining the drug expense and the estimated quality-adjusted life year (QALY) using a dataset from a double-blind placebo-controlled clinical trial. Results: A total of 238 records were included for analysis. The estimated utility decreased with increasing severity of rhinitis. Patients with comorbid asthma showed lower utility. A negative and significant correlation was seen between the TSS and utility in both 2019 and 2020. The estimated equations were: Y(utility) = −0.0161∗X(TSS) + 1.005 in non-asthmatic JCP patients. The ICER of active SLIT to the placebo was estimated to be 4,049,720 and 6,011,218 JPY/QALY in the first and second year, respectively. Conclusions: It is possible to reasonably predict utility from the total naso-ocular symptom score by using regression models. In the estimated algorithm, pre-seasonal SLIT for JCP is cost-effective. |
| first_indexed | 2024-04-13T15:45:00Z |
| format | Article |
| id | doaj.art-0d6b2e35b9564e328e1b59f476873385 |
| institution | Directory Open Access Journal |
| issn | 1323-8930 |
| language | English |
| last_indexed | 2024-04-13T15:45:00Z |
| publishDate | 2022-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Allergology International |
| spelling | doaj.art-0d6b2e35b9564e328e1b59f4768733852022-12-22T02:41:00ZengElsevierAllergology International1323-89302022-04-01712207213Mapping naso-ocular symptom scores to EQ-5D-5L utility values in Japanese cedar pollinosisHiroshi Kumanomidou0Kengo Kanai1Aiko Oka2Takenori Haruna3Yuji Hirata4Sei-ichiro Makihara5Takaya Higaki6Maki Akamatsu7Yoshitaka Okamoto8Shunya Ikeda9Mitsuhiro Okano10Department of Otorhinolaryngology, International University of Health and Welfare School of Medicine, Narita, Japan; Kumanomidou ENT Clinic, Tokyo, JapanDepartment of Otorhinolaryngology, International University of Health and Welfare School of Medicine, Narita, JapanDepartment of Otorhinolaryngology, International University of Health and Welfare School of Medicine, Narita, JapanDepartment of Otorhinolaryngology-Head & Neck Surgery, Himeji St. Mary's Hospital, Himeji, JapanDepartment of Otorhinolaryngology-Head & Neck Surgery, Kagawa Prefectural Central Hospital, Takamatsu, JapanDepartment of Otorhinolaryngology-Head & Neck Surgery, Kagawa Rosai Hospital, Marugame, JapanDepartment of Otolaryngology-Head & Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, JapanDepartment of Otorhinolaryngology, International University of Health and Welfare School of Medicine, Narita, JapanChiba Rosai Hospital, Ichihara, JapanDepartment of Public Health, International University of Health and Welfare School of Medicine, Narita, JapanDepartment of Otorhinolaryngology, International University of Health and Welfare School of Medicine, Narita, Japan; Department of Otolaryngology-Head & Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; Corresponding author. Department of Otorhinolaryngology, International University of Health and Welfare Graduate School of Medicine, 4-3 Kozunomori, Narita 286-8686, Japan.Background: The total naso-ocular symptom score (TSS) is widely used as an endpoint to evaluate the severity of seasonal allergic rhinitis. However, it is not a generic preference-based measure. We sought to develop an algorithm for mapping between the TSS and health utility in Japanese cedar pollinosis (JCP). We also performed a cost-utility analysis of sublingual immunotherapy (SLIT) for JCP by using this algorithm. Methods: Patients with JCP filled out the TSS questionnaire and EQ-5D-5L simultaneously during the pollen season in 2019 and in 2020. We estimated a direct utility mapping model by regressing responses to individual TSS questions directly onto utility. The incremental cost-effectiveness ratio (ICER) of active SLIT to a placebo was determined by examining the drug expense and the estimated quality-adjusted life year (QALY) using a dataset from a double-blind placebo-controlled clinical trial. Results: A total of 238 records were included for analysis. The estimated utility decreased with increasing severity of rhinitis. Patients with comorbid asthma showed lower utility. A negative and significant correlation was seen between the TSS and utility in both 2019 and 2020. The estimated equations were: Y(utility) = −0.0161∗X(TSS) + 1.005 in non-asthmatic JCP patients. The ICER of active SLIT to the placebo was estimated to be 4,049,720 and 6,011,218 JPY/QALY in the first and second year, respectively. Conclusions: It is possible to reasonably predict utility from the total naso-ocular symptom score by using regression models. In the estimated algorithm, pre-seasonal SLIT for JCP is cost-effective.http://www.sciencedirect.com/science/article/pii/S1323893021001416Allergic rhinitisEQ-5D-5LMappingQALYSymptom score |
| spellingShingle | Hiroshi Kumanomidou Kengo Kanai Aiko Oka Takenori Haruna Yuji Hirata Sei-ichiro Makihara Takaya Higaki Maki Akamatsu Yoshitaka Okamoto Shunya Ikeda Mitsuhiro Okano Mapping naso-ocular symptom scores to EQ-5D-5L utility values in Japanese cedar pollinosis Allergology International Allergic rhinitis EQ-5D-5L Mapping QALY Symptom score |
| title | Mapping naso-ocular symptom scores to EQ-5D-5L utility values in Japanese cedar pollinosis |
| title_full | Mapping naso-ocular symptom scores to EQ-5D-5L utility values in Japanese cedar pollinosis |
| title_fullStr | Mapping naso-ocular symptom scores to EQ-5D-5L utility values in Japanese cedar pollinosis |
| title_full_unstemmed | Mapping naso-ocular symptom scores to EQ-5D-5L utility values in Japanese cedar pollinosis |
| title_short | Mapping naso-ocular symptom scores to EQ-5D-5L utility values in Japanese cedar pollinosis |
| title_sort | mapping naso ocular symptom scores to eq 5d 5l utility values in japanese cedar pollinosis |
| topic | Allergic rhinitis EQ-5D-5L Mapping QALY Symptom score |
| url | http://www.sciencedirect.com/science/article/pii/S1323893021001416 |
| work_keys_str_mv | AT hiroshikumanomidou mappingnasoocularsymptomscorestoeq5d5lutilityvaluesinjapanesecedarpollinosis AT kengokanai mappingnasoocularsymptomscorestoeq5d5lutilityvaluesinjapanesecedarpollinosis AT aikooka mappingnasoocularsymptomscorestoeq5d5lutilityvaluesinjapanesecedarpollinosis AT takenoriharuna mappingnasoocularsymptomscorestoeq5d5lutilityvaluesinjapanesecedarpollinosis AT yujihirata mappingnasoocularsymptomscorestoeq5d5lutilityvaluesinjapanesecedarpollinosis AT seiichiromakihara mappingnasoocularsymptomscorestoeq5d5lutilityvaluesinjapanesecedarpollinosis AT takayahigaki mappingnasoocularsymptomscorestoeq5d5lutilityvaluesinjapanesecedarpollinosis AT makiakamatsu mappingnasoocularsymptomscorestoeq5d5lutilityvaluesinjapanesecedarpollinosis AT yoshitakaokamoto mappingnasoocularsymptomscorestoeq5d5lutilityvaluesinjapanesecedarpollinosis AT shunyaikeda mappingnasoocularsymptomscorestoeq5d5lutilityvaluesinjapanesecedarpollinosis AT mitsuhirookano mappingnasoocularsymptomscorestoeq5d5lutilityvaluesinjapanesecedarpollinosis |